• Tue, June 7, 2022
  • Wed, June 8, 2022

David Lebowitz Maintained (ARQT) at Buy with Increased Target to $39 on, Jun 7th, 2022

David Lebowitz of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Increased Target from $36 to $39 on, Jun 7th, 2022.

David has made no other calls on ARQT in the last 4 months.



There is 1 other peer that has a rating on ARQT. Out of the 1 peers that are also analyzing ARQT, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Uy Ear of "Mizuho" Maintained at Strong Buy with Decreased Target to $57 on, Thursday, April 7th, 2022

WOPRAI
Market Predictions Driven by AI

Like: 👍